Home › Activist investors › Rubric Capital
Other large holder. Positions and campaigns from Rubric Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Integra Lifesciences Holdings Corp. | 9.45%7,353,934 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 | Nov 13, 2024 | Decreased Nov 16, 2026 | ▼ 0.52 pts | Decreased | 13F: none stated |
| Enovis Corporation | 9.19%5,300,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 10, 2019 | Increased Nov 16, 2026 | ▲ 2.42 pts | Increased | 13F: none stated |
| MannKind Corporation | 9.15%29,430,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 | Nov 14, 2025 | Increased Nov 16, 2026 | ▲ 3.55 pts | Increased | 13F: none stated |
| MeiraGTx Holdings Plc | 8.77%8,427,279 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 11, 2026 | May 14, 2025 | Decreased Nov 16, 2026 | ▼ 0.70 pts | Decreased | 13F: none stated |
| Liberty Latin America LTD. | 8.76%17,548,084 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Nov 14, 2025 | Decreased Nov 16, 2026 | ▼ 0.94 pts | Decreased | 13F: none stated |
| Cimpress PLC | 8.43%2,075,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Feb 10, 2023 | Increased Nov 16, 2026 | ▲ 1.24 pts | Increased | 13F: none stated |
| Ecovyst Inc. | 8.02%8,711,888 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Aug 14, 2025 | Increased Nov 16, 2026 | ▲ 0.52 pts | Increased | 13F: none stated |
| Liberty Global PLC | 7.31%24,480,483 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Feb 13, 2024 | Increased Nov 16, 2026 | ▲ 1.04 pts | Increased | 13F: none stated |
| Edesa Biotech, Inc. | 7.00%622,200 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 13, 2026 | May 14, 2025 | Decreased Nov 16, 2026 | ▼ 0.53 pts | Decreased | 13F: none stated |
| Abeona Therapeutics Inc. | 5.84%3,339,707 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 4.78 pts | Increased | 13F: none stated |
| Six Flags Entertainment Corporation | 5.81%5,944,841 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| ADMA Biologics, Inc. | 5.57%12,352,584 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 1.40 pts | Increased | 13F: none stated |
| Ardelyx, Inc. | 5.53%13,908,138 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Nov 15, 2023 | Decreased Nov 16, 2026 | ▼ 0.97 pts | Decreased | 13F: none stated |
| CoreCivic, Inc. | 4.66%4,030,385 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 14, 2025 | Increased Nov 16, 2026 | ▲ 1.78 pts | Increased | 13F: none stated |
| PennyMac Financial Services, Inc. | 4.62%2,400,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Aug 10, 2020 | Increased Nov 16, 2026 | ▲ 1.35 pts | Increased | 13F: none stated |
| QuidelOrtho Corporation | 4.57%3,133,148 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 | Nov 15, 2023 | Decreased Nov 16, 2026 | ▼ 0.25 pts | Decreased | 13F: none stated |
| Nurix Therapeutics, Inc. | 4.55%4,966,827 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 30, 2026 | Feb 13, 2026 | Decreased Nov 16, 2026 | ▼ 2.42 pts | Decreased | 13F: none stated |
| Ftai Aviation LTD. | 4.11%4,200,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | May 14, 2025 | Increased Nov 16, 2026 | ▲ 1.19 pts | Increased | 13F: none stated |
| The GEO Group, Inc. | 3.92%5,187,353 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | May 14, 2025 | Increased Nov 16, 2026 | ▲ 0.78 pts | Increased | 13F: none stated |
| Newell Brands Inc. | 3.87%16,500,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Nov 14, 2025 | Increased Nov 16, 2026 | ▲ 0.12 pts | Increased | 13F: none stated |
| Indivior Pharmaceuticals, Inc. | 3.27%3,862,989 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 9, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Biohaven LTD. | 3.23%4,875,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 2.09 pts | Increased | 13F: none stated |
| Viatris Inc. | 3.14%36,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 11, 2023 | Increased Nov 16, 2026 | ▲ 0.17 pts | Increased | 13F: none stated |
| Supernus Pharmaceuticals, Inc. | 2.99%1,739,892 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Matthews International Corporation | 2.82%878,734 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jun 30, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Schrodinger, Inc. | 2.68%1,980,830 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | May 13, 2022 | Decreased Nov 16, 2026 | ▼ 5.97 pts | Decreased | 13F: none stated |
| Amneal Pharmaceuticals, Inc. | 2.67%8,536,755 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Aug 11, 2023 | Decreased Nov 16, 2026 | ▼ 0.51 pts | Decreased | 13F: none stated |
| Core Scientific, Inc. | 2.17%7,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Driven Brands Holdings Inc. | 2.14%3,528,045 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 | May 15, 2026 | Decreased Nov 16, 2026 | ▼ 1.07 pts | Decreased | 13F: none stated |
| Collegium Pharmaceutical, Inc. | 2.01%625,819 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | May 14, 2020 | Decreased Nov 16, 2026 | ▼ 1.92 pts | Decreased | 13F: none stated |
| Vistance Networks, Inc. | 1.96%4,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 | May 15, 2026 | Increased Nov 16, 2026 | ▲ 1.10 pts | Increased | 13F: none stated |
| Fluor Corporation | 1.93%2,469,762 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Feb 14, 2022 | Decreased Nov 16, 2026 | ▼ 1.82 pts | Decreased | 13F: none stated |
| Service Properties Trust | 1.79%2,322,880 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 1.09 pts | Increased | 13F: none stated |
| StubHub Holdings, Inc. | 1.73%6,213,747 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 | Feb 13, 2026 | Increased Nov 16, 2026 | ▲ 0.34 pts | Increased | 13F: none stated |
| Arbutus Biopharma Corporation | 1.69%3,343,932 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 10, 2026 | Feb 10, 2023 | Decreased Nov 16, 2026 | ▼ 2.12 pts | Decreased | 13F: none stated |
| The Andersons, Inc. | 1.42%477,826 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Feb 13, 2026 | Decreased Nov 16, 2026 | ▼ 1.52 pts | Decreased | 13F: none stated |
| Aptiv PLC | 1.31%2,651,364 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Nov 16, 2026 | — | — | New | 13F: none stated |
| Establishment Labs Holdings Inc. | 1.24%370,098 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 5, 2026 | Aug 14, 2026 | Decreased Nov 16, 2026 | ▼ 1.07 pts | Decreased | 13F: none stated |
| Sonoco Products Company | 1.21%1,192,329 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 16, 2026 | Aug 14, 2026 | Increased Nov 16, 2026 | ▲ 0.05 pts | Increased | 13F: none stated |
| Roivant Sciences Ltd. | 1.04%7,481,524 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Feb 10, 2023 | Increased Nov 16, 2026 | ▲ 0.21 pts | Increased | 13F: none stated |
| Heron Therapeutics, Inc. /De/ | 15.9%30,046,828 shares | Schedule 13D/A, filed Oct 17, 2025 | Jul 25, 2023 | Increased Oct 17, 2025 | ▼ 1.60 pts | — | Standard Item 4 language |
| Zymeworks Inc. | 9.86%7,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 4, 2026 | Feb 10, 2023 | — | 0.00 pts | — | 13F: none stated |
| Prothena Corporation plc | 9.74%5,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | Nov 14, 2025 | — | 0.00 pts | — | 13F: none stated |
| Xperi Inc. | 9.2%4,143,744 shares | Schedule 13D/A, filed Jun 11, 2024 | Jan 23, 2024 | — | — | — | Standard Item 4 language |
| Orthofix Medical Inc. | 9.14%3,721,715 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | May 12, 2023 | — | 0.00 pts | — | 13F: none stated |
| ARS Pharmaceuticals, Inc. | 8.50%8,540,861 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Aug 15, 2022 | — | ▼ 0.09 pts | — | 13F: none stated |
| Talen Energy Corporation | 8.28%3,602,171 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Nov 13, 2024 | — | ▲ 0.76 pts | — | 13F: none stated |
| Edgewell Personal Care Company | 7.60%3,504,525 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 | Feb 13, 2026 | — | ▼ 0.09 pts | — | 13F: none stated |
| Mativ Holdings, Inc. | 7.25%4,000,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 | Nov 14, 2022 | — | ▲ 0.03 pts | — | 13F: none stated |
| Arcutis Biotherapeutics, Inc. | 6.66%8,421,577 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Aug 15, 2022 | — | ▲ 0.08 pts | — | 13F: none stated |
| OPKO Health, Inc. | 6.44%47,791,243 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 20, 2026 | May 10, 2024 | — | ▲ 0.03 pts | — | 13F: none stated |
| Delek US Holdings, Inc. | 4.43%2,687,449 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Nov 13, 2024 | — | ▲ 0.04 pts | — | 13F: none stated |
| Seaport Entertainment Group Inc. | 4.43%568,530 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Nov 13, 2024 | — | ▼ 0.01 pts | — | 13F: none stated |
| Target Hospitality Corp. | 2.60%2,586,389 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 | May 10, 2019 | — | 0.00 pts | — | 13F: none stated |
| Dnow Inc. | 2.16%3,898,635 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 | May 15, 2026 | — | ▲ 0.01 pts | — | 13F: none stated |
| Hudson Pacific Properties Inc. | 1.88%1,019,598 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 | Aug 14, 2026 | — | 0.00 pts | — | 13F: none stated |
| Compass, Inc. | 1.07%8,218,394 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 3, 2026 | Feb 13, 2026 | — | ▼ 0.01 pts | — | 13F: none stated |
| Mereo BioPharma Group plc | — | Schedule 13D/A, filed Jun 17, 2024stake not read from this filing’s format: see the filing | Jun 16, 2023 | — | — | — | Standard Item 4 language |
| TherapeuticsMD, Inc. | — | Schedule 13D/A, filed Nov 17, 2023stake not read from this filing’s format: see the filing | Jun 30, 2023 | — | — | — | Standard Item 4 language |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“On October 15, 2025, the Issuer filed a Current Report on Form 8-K with the SEC disclosing that it obtained Stockholder Approval, as a result of which, the 94,610 shares of Preferred Stock beneficially owned by the Reporting Persons automatically converted, without any action on the part of the holders thereof, into 946,100 Shares. Additionally, as previously disclosed, on August 8, 2025, a certain…”
“Item 4 is hereby amended to add the following: The Reporting Persons are deeply concerned by the Issuer’s continued poor stock performance. The Reporting Persons intend to continue monitoring the Issuer’s performance and will not hesitate to take any action that they believe is necessary to protect the best interests of stockholders.”
“Item 4 of the Schedule 13D is hereby amended by adding the following. On June 14, 2024, the Issuer filed a Form 8-K dated June 14, 2024 (the “Form 8-K”), and a Form 424B5 dated June 14, 2024, with the Securities and Exchange Commission in connection with an underwritten offering of 12,531,300 ADSs (such Form 424B5, “Form 424B5,” and such offering, the “Offering”) by the Issuer. The Reporting Persons…”
“Item 4 of the Schedule 13D is hereby amended by adding the following: As disclosed in the Current Report on Form 8-K filed by the Issuer with the SEC on May 5, 2023, the Issuer and Rubric Capital entered into a Subscription Agreement on May 1, 2023 (the “ Subscription Agreement ”) p ursuant to which the Issuer agreed to sell to Rubric Capital, or one or more of its affiliates, up to an aggregate of…”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. /De/ | Settled (agreement with the company) | Feb 22, 2023 | Feb 6, 2023 | — | latest (5) | — |
| Xperi Inc.Board seats | Contested vote held — 0 of 2 of the activist's nominees elected | May 24, 2024 | Jan 23, 2024 | Proxy contest filed | latest (13) | how managers voted |
| Mereo BioPharma Group plc | Settled (agreement with the company) | Apr 15, 2024 | May 26, 2022 | — | latest (2) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| ANI Pharmaceuticals, Inc. | 1.15% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Dec 31, 2025 | Not in the latest 13F | Nov 16, 2026 |
| Mercury General Corporation | 2.78% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 30, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Teva Pharmaceutical Industries LTD. | 1.34% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jun 30, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Trevi Therapeutics, Inc. | 1.76% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jul 31, 2026 | Not in the latest 13F | Nov 16, 2026 |
| Tripadvisor, Inc. | 2.08% | 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Jun 30, 2026 | Not in the latest 13F | Nov 16, 2026 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
Contested director elections at which Rubric Capital had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.
| Manager | Backed the activist | Xperi Inc. 2024 |
|---|---|---|
| BlackRock | 0 of 1 (0%) | Company |
| Vanguard | 0 of 1 (0%) | Company |
| John Hancock | 0 of 1 (0%) | Company |
| Dimensional | 0 of 1 (0%) | Company |
| JPMorgan | 1 of 1 (100%) | Activist |
| Fidelity | 0 of 1 (0%) | Company |
| State Street | 0 of 1 (0%) | Company |
| ADVISORS SERIES TRUST | 1 of 1 (100%) | Activist |
| Charles Schwab | 0 of 1 (0%) | Company |
| Hartford | 1 of 1 (100%) | Activist |
| New York Life | 1 of 1 (100%) | Activist |
| Invesco | 0 of 1 (0%) | Company |
| Columbia Threadneedle | 0 of 1 (0%) | Company |
| MoA Funds Corp | 0 of 1 (0%) | Company |
| TIAA | 0 of 1 (0%) | Company |
| Prudential/PGIM | 0 of 1 (0%) | Company |
| Brighthouse | 0 of 1 (0%) | Company |
| Equitable | 0 of 1 (0%) | Company |
| Nationwide | 0 of 1 (0%) | Company |
| Jackson National | 0 of 1 (0%) | Company |
— = no N-PX votes on the contested director elections found for that manager.
Result: Form 8-K, Item 5.07. Activist’s nominees: Deborah S. Conrad (not elected (8-k tally)); Thomas A. Lacey (not elected (8-k tally)). Company’s nominees: Darcy Antonellis (elected (8-k tally)); Laura J. Durr (elected); David C. Habiger (elected); Jon E. Kirchner (elected); Christopher Seams (elected).
| Manager | Stance | FOR the activist’s nominees | Avg. shares FOR each activist nominee | FOR the company’s nominees |
|---|---|---|---|---|
| BlackRock | Backed the company's nominees | 0 of 26 fund votes | 0 | 65 of 65 fund votes |
| Vanguard | Backed the company's nominees | 0 of 30 fund votes | 0 | 75 of 75 fund votes |
| John Hancock | Backed the company's nominees | 0 of 10 fund votes | 0 | 25 of 25 fund votes |
| Dimensional | Backed the company's nominees | 0 of 34 fund votes | 0 | 85 of 85 fund votes |
| JPMorgan | Backed the activist's nominees | 10 of 10 fund votes | 666,424 | 15 of 25 fund votes |
| Fidelity | Backed the company's nominees | 0 of 28 fund votes | 0 | 70 of 70 fund votes |
| State Street | Backed the company's nominees | 0 of 20 fund votes | 0 | 50 of 50 fund votes |
| ADVISORS SERIES TRUST | Backed the activist's nominees | 2 of 2 fund votes | 285,661 | 3 of 5 fund votes |
| Charles Schwab | Backed the company's nominees | 0 of 10 fund votes | 0 | 25 of 25 fund votes |
| Hartford | Backed the activist's nominees | 2 of 2 fund votes | 170,814 | 3 of 5 fund votes |
| New York Life | Backed the activist's nominees | 2 of 2 fund votes | 165,907 | 3 of 5 fund votes |
| Invesco | Backed the company's nominees | 0 of 8 fund votes | 0 | 20 of 20 fund votes |
| Columbia Threadneedle | Backed the company's nominees | 0 of 4 fund votes | 0 | 10 of 10 fund votes |
| MoA Funds Corp | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| TIAA | Backed the company's nominees | 0 of 12 fund votes | 0 | 30 of 30 fund votes |
| Prudential/PGIM | Backed the company's nominees | 2 of 6 fund votes | 50,197 | 13 of 15 fund votes |
| Brighthouse | Backed the company's nominees | 2 of 10 fund votes | 63,043 | 23 of 25 fund votes |
| Equitable | Backed the company's nominees | 0 of 14 fund votes | 0 | 35 of 35 fund votes |
| Nationwide | Backed the company's nominees | 0 of 12 fund votes | 0 | 25 of 30 fund votes |
| Jackson National | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| AIG/SunAmerica | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| Voya | Backed the company's nominees | 0 of 8 fund votes | 0 | 20 of 20 fund votes |
| Lincoln Financial | Backed the company's nominees | 2 of 8 fund votes | 24,748 | 18 of 20 fund votes |
| WisdomTree | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| BNY Mellon | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| QUANTITATIVE MASTER SERIES LLC | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| American Century | Backed the company's nominees | 0 of 8 fund votes | 0 | 20 of 20 fund votes |
| Principal | Backed the company's nominees | 2 of 6 fund votes | 4,946 | 13 of 15 fund votes |
| Nushares ETF Trust | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| Russell Investments | Backed the company's nominees | 0 of 8 fund votes | 0 | 20 of 20 fund votes |
| DWS | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| Thrivent | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| GuideStone | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| Allianz | Backed the company's nominees | 0 of 6 fund votes | 0 | 15 of 15 fund votes |
| PFM Multi-Manager Series Trust | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| Direxion Shares ETF Trust | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| Empower | Backed the company's nominees | 0 of 2 fund votes | 0 | 4 of 5 fund votes |
| Catholic Responsible Investments Funds | Backed the company's nominees | 0 of 2 fund votes | 0 | 5 of 5 fund votes |
| Northern Trust | Backed the company's nominees | 0 of 4 fund votes | 0 | 8 of 10 fund votes |
| T. Rowe Price | Backed the company's nominees | 0 of 4 fund votes | 0 | 10 of 10 fund votes |
31 smaller managers not shown.
Source: N-PX reports filed by 71 managers for the meeting of May 24, 2024; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Heron Therapeutics, Inc. /De/ | Settlement | agreement with the company | Aug 12, 2025 | Feb 6, 2023 |
| Xperi Inc. | Contest vote: nominees not elected | 0 of 2 of the activist's nominees elected | May 24, 2024 | Jan 23, 2024 |
| Mereo BioPharma Group plc | Settlement | agreement with the company | Apr 15, 2024 | May 26, 2022 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 4 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“…he other parties thereto (a copy of which has been filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 23, 2023), with respect to the standstill provision that would have prevented the aggregate beneficial ownership of Velan and Rubric from exceeding 15.0% of the Company’s outstanding voting securities.” 8-K, Jul 24, 2023
“(i) The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 5.02 by reference. 2 Pursuant to the Cooperation Agreement, effective on February 21, 2023, the Board increased the size of the Board from seven to eight directors and appointed Adam Morgan, Craig Collard, and Kevin Kotler to the Board.” 8-K, Feb 22, 2023
“Further, the ultimate appointment of any Replacement Director is subject to the Board’s determination that such Replacement Director is reasonably acceptable.” 8-K, Feb 22, 2023
“(3) cause Mr. Morgan to be appointed to the Nominating & Corporate Governance Committee, Mr. Collard to be appointed to the Compensation Committee and Mr. Kotler to be appointed to the Audit Committee and Compensation Committee; and (4) include the New Directors in the Company’s slate of nominees for the election of directors at the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”) and recommend that the Company’s stockholders vote in favor of their el…” 8-K, Feb 22, 2023
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Rubric Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Jane Street Group, LLC | Schedule 13G | May 26, 2026 | 7.5% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.1% |
| Kenneth Griffin | Schedule 13G | Aug 5, 2026 | 6.5% |
| Jericho Capital Asset Management L.P. | Schedule 13G | Aug 14, 2026 | 7.2% |
| Pentwater Capital Management LP | Schedule 13G | Aug 14, 2026 | 0.4% |
| Valiant Capital Management, L.P. | Schedule 13G | Aug 14, 2026 | 5.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock, Inc. | Schedule 13G | Jul 30, 2026 | 14.4% |
| Darlington Partners Capital Management, LP | Schedule 13G | Aug 14, 2026 | 7.5% |
| H Partners Management, LLC | Schedule 13D | Nov 16, 2026 | 7.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| Vanguard Portfolio Management | Schedule 13G | Jul 31, 2026 | 4.0% |
| Oaktree Capital Management LP | Schedule 13G | Aug 10, 2026 | 6.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Millennium Management LLC | Schedule 13G | Aug 6, 2026 | 6.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Barrow Hanley Mewhinney & Strauss LLC | Schedule 13G | Aug 12, 2026 | 5.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Juan Jose Chacon Quiros | Schedule 13G | Feb 19, 2026 | 4.9% |
| Brown Advisory Inc | Schedule 13G | May 15, 2026 | 5.4% |
| BlackRock, Inc. | Schedule 13G | Jul 28, 2026 | 5.4% |
| JW Asset Management, LLC | Schedule 13G | Jul 31, 2026 | 9.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Daniel Kaufman | Schedule 13G | Mar 27, 2026 | 5.2% |
| Funicular Funds, LP | Schedule 13G | Apr 6, 2026 | 5.3% |
| AIGH Capital Management LLC | Schedule 13G | Apr 28, 2026 | 5.4% |
| Nantahala Capital Partners Limited Partnership | Schedule 13G | May 15, 2026 | 5.8% |
| Nantahala Capital Management, LLC | Schedule 13G | May 15, 2026 | 10.0% |
| Montanova Capital, LLC | Schedule 13G | Aug 14, 2026 | 0.9% |
| James Russell Revocable Trust | Schedule 13D | Oct 23, 2026 | 6.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Helix Partners Management LP | Schedule 13G | Apr 7, 2026 | 8.6% |
| FF Hybrid, LP | Schedule 13G | Apr 8, 2026 | 9.4% |
| The RMR Group LLC | Schedule 13D | Apr 9, 2026 | 6.8% |
| Charles Schwab Investment Management Inc | Schedule 13G | May 14, 2026 | 4.7% |
| Vanguard Portfolio Management | Schedule 13G | Jul 31, 2026 | 5.1% |
| Capital World Investors | Schedule 13G | Aug 12, 2026 | 5.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Vanguard Portfolio Management | Schedule 13G | Apr 29, 2026 | 5.3% |
| Vanguard Capital Management | Schedule 13G | Apr 30, 2026 | 5.1% |
| Philosophy Capital Management LLC | Schedule 13G | May 15, 2026 | 6.8% |
| T. Rowe Price Investment Management, Inc. | Schedule 13G | May 15, 2026 | 5.2% |
| Cohen & Steers, Inc. | Schedule 13G | Aug 14, 2026 | 18.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Janus Henderson Group PLC | Schedule 13G | May 15, 2026 | 11.7% |
| JANUS HENDERSON GROUP Ltd. | Schedule 13G | Jul 8, 2026 | 5.7% |
| Woodline Partners LP | Schedule 13G | Aug 14, 2026 | 5.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| The Vanguard Group | Schedule 13G | Jan 30, 2026 | 10.5% |
| Wellington Management Group LLP | Schedule 13G | Feb 10, 2026 | 5.8% |
| Vanguard Capital Management | Schedule 13G | Apr 29, 2026 | 5.2% |
| Vanguard Portfolio Management | Schedule 13G | Apr 29, 2026 | 5.6% |
| Engine Capital | 13F | May 15, 2026 | 2.9% |
| Dimensional Fund Advisors LP | Schedule 13G | Jul 14, 2026 | 4.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Invesco Ltd. | Schedule 13G | Feb 12, 2026 | 5.0% |
| Vanguard Capital Management | Schedule 13G | Apr 29, 2026 | 5.1% |
| State Street Corporation | Schedule 13G | Aug 7, 2026 | 7.4% |
| Nantahala Capital | 13F | Aug 14, 2026 | 1.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Mangrove Partners | 13F | Feb 17, 2026 | 4.6% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| FMR LLC | Schedule 13G | May 6, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Quad-C Partners IX, L.P. | Schedule 13G | Aug 29, 2025 | 5.1% |
| FMR LLC | Schedule 13G | Nov 5, 2025 | 12.7% |
| SB Investment Advisers (UK) Limited | Schedule 13G | Feb 17, 2026 | 4.5% |
| Vanguard Portfolio Management | Schedule 13G | Apr 29, 2026 | 8.2% |
| BlackRock, Inc. | Schedule 13G | Jul 27, 2026 | 7.0% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Brandes Investment Partners, LP | Schedule 13G | Sep 5, 2025 | 10.9% |
| American Century Investment Management, Inc. | Schedule 13G | Nov 14, 2025 | 8.5% |
| Dimensional Fund Advisors LP | Schedule 13G | Jan 21, 2026 | 5.6% |
| Vanguard Capital Management | Schedule 13G | Apr 29, 2026 | 5.1% |
| Vanguard Portfolio Management | Schedule 13G | Apr 29, 2026 | 6.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| First Trust Portfolios L.P. | Schedule 13G | Oct 31, 2025 | 0.5% |
| Vanguard Portfolio Management | Schedule 13G | Apr 28, 2026 | 7.1% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| FMR LLC | Schedule 13G | Nov 5, 2025 | 11.5% |
| Commodore Capital LP | Schedule 13G | Nov 14, 2025 | 4.9% |
| Baker Bros. Advisors LP | Schedule 13G | Feb 17, 2026 | 7.2% |
| Redmile Group, LLC | Schedule 13G | Apr 24, 2026 | 9.9% |
| Vestal Point Capital, LP | Schedule 13G | May 15, 2026 | 6.3% |
| Deep Track Capital, LP | Schedule 13G | May 15, 2026 | 6.2% |
| Vanguard Capital Management | Schedule 13G | Jul 31, 2026 | 5.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| PointState Capital LP | Schedule 13G | Jan 9, 2026 | 7.2% |
| WestCap Management, LLC | Schedule 13G | Jan 21, 2026 | 11.6% |
| Deer VIII & Co. L.P. | Schedule 13G | Apr 29, 2026 | 6.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Logos Global Management LP | Schedule 13G | Jun 4, 2025 | 5.5% |
| Wellington Management Group LLP | Schedule 13G | Jun 5, 2025 | 0.2% |
| Scully William P | Schedule 13G | Aug 13, 2025 | 9.9% |
| Fennell Todd W. | Schedule 13G | Aug 13, 2025 | 8.1% |
| ADAR1 Capital Management, LLC | Schedule 13G | Aug 14, 2025 | 6.3% |
| T. Rowe Price Associates, Inc. | Schedule 13G | Aug 14, 2025 | 0.1% |
| BlackRock, Inc. | Schedule 13G | Oct 17, 2025 | 5.7% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Dimensional Fund Advisors LP | Schedule 13G | Jul 15, 2025 | 5.0% |
| Massachusetts Financial Services Company | Schedule 13G | Aug 4, 2025 | 4.9% |
| Cooper Creek Partners Management LLC | Schedule 13G | Aug 13, 2025 | 6.2% |
| AQR Capital Management, LLC | Schedule 13G | Feb 13, 2026 | 5.0% |
| BlackRock, Inc. | Schedule 13G | Apr 24, 2026 | 11.4% |
| Vanguard Portfolio Management | Schedule 13G | Apr 29, 2026 | 5.5% |
| Vanguard Capital Management | Schedule 13G | Apr 30, 2026 | 5.2% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| State Street Corporation | Schedule 13G | May 12, 2026 | 6.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Hotchkis and Wiley Capital Management, LLC | Schedule 13G | Aug 13, 2025 | 9.6% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Capital International Investors | Schedule 13G | Jan 3, 2025 | 10.6% |
| Shikiar Asset Management Inc | Schedule 13G | Feb 5, 2025 | 6.3% |
| BlackRock, Inc. | Schedule 13G | Feb 5, 2025 | 9.4% |
| Washington State Investment Board | Schedule 13G | Feb 14, 2025 | 2.1% |
| Capital World Investors | Schedule 13G | Aug 13, 2025 | 5.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Cooper Creek Partners Management LLC | Schedule 13G | Feb 14, 2025 | 5.6% |
| BlackRock, Inc. | Schedule 13G | Apr 28, 2025 | 14.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Wolf Hill Capital Management, LP | Schedule 13G | Feb 14, 2025 | 5.7% |
| FMR LLC | Schedule 13G | Aug 6, 2025 | 2.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Velan Capital Master Fund LP | Schedule 13D | Feb 18, 2025 | 10.0% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock, Inc. | Schedule 13G | Apr 17, 2025 | 7.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Pershing Square | Schedule 13D | Aug 7, 2024 | 40.1% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Two Seas Capital LP | 13F | Aug 14, 2024 | 1.2% |
| Sachem Head | 13F | Nov 14, 2024 | 2.7% |
| Carronade Capital | 13F | Nov 14, 2024 | 1.5% |
| The Vanguard Group | Schedule 13G | Jan 8, 2025 | 10.4% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock, Inc. | Schedule 13G | Apr 23, 2025 | 7.9% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Invesco Ltd. | Schedule 13G | May 9, 2025 | 5.3% |
| Holder | Form | Date | Stake |
|---|---|---|---|
| Engine Capital, L.P. | Schedule 13D | Nov 3, 2023 | — |